PT - JOURNAL ARTICLE AU - Wu, Kangyun AU - Zhang, Yong AU - Austin, Stephen R. AU - Declue, Huqing Yin AU - Byers, Derek E. AU - Crouch, Erika C. AU - Holtzman, Michael J. TI - Lung remodeling regions in long-term Covid-19 feature basal epithelial cell reprogramming AID - 10.1101/2022.09.17.22280043 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.17.22280043 4099 - http://medrxiv.org/content/early/2022/09/19/2022.09.17.22280043.short 4100 - http://medrxiv.org/content/early/2022/09/19/2022.09.17.22280043.full AB - Respiratory viruses, including SARS-CoV-2, can trigger chronic lung disease that persists and even progresses after expected clearance of infectious virus. To gain an understanding of this process, we examined a series of consecutive fatal cases of Covid-19 that came to autopsy at 27-51 d after hospital admission. In each patient, we identify a stereotyped bronchiolar-alveolar pattern of lung remodeling with basal epithelial cell hyperplasia and mucinous differentiation. Remodeling regions also feature macrophage infiltration and apoptosis and a marked depletion of alveolar type 1 and 2 epithelial cells. This entire pattern closely resembles findings from an experimental model of post-viral lung disease that requires basal-epithelial stem cell growth, immune activation, and differentiation. The present results thereby provide evidence of possible basal epithelial cell reprogramming in long-term Covid-19 as well and thereby a pathway for explaining and correcting lung dysfunction in this type of disease.Competing Interest StatementMJH is Founder of NuPeak Therapeutics and a scientific advisor for Lonza Bend. DEB is a consultant for AstraZeneca. The other authors have no potential financial conflicts of interest to declare.Funding StatementThis work was supported by grants from the National Institutes of Health (National Heart, Lung, and Blood Institute R35-HL145242, National Institute of Allergy and Infectious Diseases R01-AI130591), Department of Defense (PR190726 and PR211069), and the Harrington Discovery Institute, Cystic Fibrosis Foundation, Bebermeyer Fund, Hardy Trust, and Schaefer Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IRB of Washington University School of Medicine.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.